Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fate TherapeuticsFATE -6.57%33 3-Year EPS without NRI Growth Rate is 28.30% as of Jun. 2026, which is 859% above its 10-year median of 2.95. GuruFocus rates FATE with a GF Score™ of 33/100 and a GF Value™ of $0.77 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,161 Biotechnology companies, Fate Therapeutics ranks better than 64.51% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 28.30% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 8.80% per year.
During the past 10 years, the average EPS without NRI Growth Rate was -4.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Fate Therapeutics was 30.50% per year. The lowest was -29.40% per year. And the median was 2.95% per year.
Fate Therapeutics (NAS:FATE) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Fate Therapeutics 3-Year EPS without NRI Growth Rate Related Terms
FATE vs IMRX, NWBO, FHTX: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, Fate Therapeutics's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fate Therapeutics 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fate Therapeutics's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Fate Therapeutics's 3-Year EPS without NRI Growth Rate falls into.
Fate Therapeutics 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 28.30% mean?
Fate Therapeutics (FATE) has a 3-Year EPS without NRI Growth Rate of 28.30% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Fate Therapeutics and its competitors. This is 859% above median its historical median of 2.95. According to the industry distribution chart, Fate Therapeutics ranks #412 out of 1161 companies in the Biotechnology industry, placing it in the top 35.5%.
Is Fate Therapeutics' 3-Year EPS without NRI Growth Rate too high?
Fate Therapeutics' current 3-Year EPS without NRI Growth Rate of 28.30% is 859% above median its 10-year median of 2.95. The Biotechnology industry median 3-Year EPS without NRI Growth Rate is 16.20. Fate Therapeutics' value of 28.30% is 74.7% above this industry median. Based on the distribution chart, Fate Therapeutics ranks #412 out of 1161 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Fate Therapeutics has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fate Therapeutics' 3-Year EPS without NRI Growth Rate compare to IMRX and NWBO?
According to the Biotechnology industry distribution chart, Fate Therapeutics ranks #412 out of 1161 companies for 3-Year EPS without NRI Growth Rate. This puts Fate Therapeutics in the upper half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 16.20. Fate Therapeutics' value of 28.30% is 74.7% above this benchmark. While the company's 10-year median is 2.95 vs. the industry median of 16.20, Fate Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 16.20, based on 1,161 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fate Therapeutics's current 3-Year EPS without NRI Growth Rate of 28.30% is 74.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Fate Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 16.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fate Therapeutics's current 3-Year EPS without NRI Growth Rate is 28.30%, which is 859% above median its own 10-year median of 2.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fate Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Fate Therapeutics (FATE) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.77, compared to a current price of $2.49 — trading 223.4% above its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 28.30%, which is 859% above median its 10-year median of 2.95 and 74.7% above the Biotechnology industry median of 16.20. Fate Therapeutics' overall GF Score™ is 33/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Fate Therapeutics (FATE), the current 3-Year EPS without NRI Growth Rate is 28.30% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fate Therapeutics (FATE) Overvalued in 2026?
Based on GuruFocus' analysis, Fate Therapeutics stock appears to be overvalued.
The current stock price of $2.49 is trading 223.4% above its estimated GF Value™ of $0.77.
GuruFocus considers Fate Therapeutics to be Significantly Overvalued.
Key valuation signals for FATE:
3-Year EPS without NRI Growth Rate: 28.30% (859% above median its 10-year median of 2.95)
GF Value™: $0.77 vs. price of $2.49 (223.4% above fair value)
Industry Position: 74.7% above the Biotechnology median (#412 of 1161)
No single metric tells the full story. See the FATE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
33GF Score
Get the complete analysis for FATE
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FATE has been successfully added to your 
